Research Synthesis: Glynac

Abstract

This paper synthesizes glynac as an aging-related intervention across 16 included source papers and 916 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct clinical evidence, 8 adjacent clinical sources, and 3 mechanistic or model-system sources, with 17 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the deficiency prevalence outcome class, null signals in the deficiency prevalence, contextual adjacent evidence and immune outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that glynac should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-glynac-v06-DAILY-2026-06-01T01-39-40Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-01.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• GlyNAC AND aging AND human trial
• glycine N-acetylcysteine AND older adults
• GlyNAC AND glutathione AND mitochondrial function
• GlyNAC AND oxidative stress AND randomized
• glycine plus NAC AND physical function AND aging

Eligibility criteria

• Sources whose primary content addresses glynac.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 101 records in the receipt-candidate union, 31 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	101
Classified source candidates	31
No extractable claims	20
None-only claim binding	5
Mixed partial-or-none claim-binding candidates	24
Partial-only claim-binding candidates	11
Strict high-confidence sources	10
Admitted final sources	16

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune, immune and inflammation, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Population / prevalence	n=5; claims=367	no extracted directional signal in 3/5 sources	2 indirect; 2 mechanistic; 1 review	limited corpus depth in this outcome class
Contextual Adjacent Evidence	n=3; claims=18	no extracted directional signal in 2/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Immune	n=3; claims=13	unclear signal in 2/3 sources	3 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=2; claims=104	unclear signal in 1/2 sources	2 indirect	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=2; claims=288	unclear signal in 2/2 sources	1 indirect; 1 mechanistic	limited corpus depth in this outcome class
Immune and Inflammation	n=1; claims=126	mixed signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Population / prevalence Outcomes

5 included sources were assigned to this outcome class. Directional coding: null=3, positive=1, unclear=1. Directness coding: indirect=2, mechanistic=2, review=1.

Contextual Adjacent Evidence Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=2, review=1.

Immune Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: review=3.

Dose / exposure Outcomes

2 included sources were assigned to this outcome class. Directional coding: mixed=1, unclear=1. Directness coding: indirect=2.

Skeletal Fracture Bone Outcomes

2 included sources were assigned to this outcome class. Directional coding: unclear=2. Directness coding: indirect=1, mechanistic=1.

Immune Inflammation Outcomes

1 included source were assigned to this outcome class. Directional coding: mixed=1. Directness coding: indirect=1.

What This Synthesis Adds

This synthesis maps 16 included sources on glynac across 6 outcome classes and 17 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 16 curated reference papers, the evidence base for glynac shows a context-dependent profile. Positive signals appear in: deficiency prevalence. Null findings dominate: deficiency prevalence, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The glynac anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the disagreement between Wang 2026 and Sekhar 2022 on dosing and pharmacokinetics (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (CORRECTING 2019, CORRECTING 2019b, Sekhar 2021) emphasize convergent signals on glynac. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
immune	0	3	null, unclear	direct clinical gap
contextual adjacent evidence	0	3	null, unclear	direct clinical gap
deficiency prevalence	0	5	null, positive, unclear	direct clinical gap
dosing and pharmacokinetics	0	2	mixed, unclear	conflict-resolution gap
immune and inflammation	0	1	mixed	direct clinical gap
skeletal, fracture, and bone	0	2	unclear	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	immune: direct clinical gap	0 direct and 3 indirect sources; direction profile: null, unclear
P2	contextual adjacent evidence: direct clinical gap	0 direct and 3 indirect sources; direction profile: null, unclear
P3	deficiency prevalence: direct clinical gap	0 direct and 5 indirect sources; direction profile: null, positive, unclear
P4	dosing and pharmacokinetics: conflict-resolution gap	0 direct and 2 indirect sources; direction profile: mixed, unclear
P5	immune and inflammation: direct clinical gap	0 direct and 1 indirect source; direction profile: mixed

Next-Study Design Recommendation

The next high-yield study for glynac should target the immune evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• CORRECTING 2019; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=immune; direction=unclear.
• CORRECTING 2019b; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=immune; direction=unclear.
• Sekhar 2021; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=contextual other; direction=unclear.
• Xu 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=skeletal fracture bone; direction=unclear; representative statistic=P = 0.0049.
• Kumar 2020; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=mixed.
• Kumar 2021; Observational; tier=B2; directness=indirect; N=—; population=older adults; endpoint=deficiency prevalence; direction=unclear; representative statistic=P < 0.05.
• Sekhar 2022; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=dosing pharmacokinetics; direction=mixed; representative statistic=P < 0.001.
• Lizzo 2022; Observational; tier=B2; directness=review; N=—; population=older adults; endpoint=deficiency prevalence; direction=positive; representative statistic=P < 0.0001.
• Wang 2026; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P = 0.007.
• Kumar 2021b; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=deficiency prevalence; direction=null.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Wang 2026 vs Sekhar 2022; Wang 2026 (unclear) vs Sekhar 2022 (mixed) on dosing pharmacokinetics

• Severity 3 null vs positive: Sekhar 2021 vs Angelini 2024; Sekhar 2021 (unclear) vs Angelini 2024 (null) on contextual other
• Severity 3 null vs positive: Sekhar 2021 vs Gut 2021; Sekhar 2021 (unclear) vs Gut 2021 (null) on contextual other
• Severity 3 null vs positive: CORRECTING 2019 vs Sekhar 2022b; CORRECTING 2019 (unclear) vs Sekhar 2022b (null) on immune
• Severity 3 null vs positive: CORRECTING 2019b vs Sekhar 2022b; CORRECTING 2019b (unclear) vs Sekhar 2022b (null) on immune
• Severity 3 null vs positive: Kumar 2023 vs Kumar 2021; Kumar 2023 (null) vs Kumar 2021 (unclear) on deficiency prevalence
• Severity 3 null vs positive: Kumar 2023 vs Lizzo 2022; Kumar 2023 (null) vs Lizzo 2022 (positive) on deficiency prevalence
• Severity 3 null vs positive: Kumar 2021 vs Kumar 2021b; Kumar 2021 (unclear) vs Kumar 2021b (null) on deficiency prevalence

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus of 16 reference papers contains no long-term, hard-endpoint mortality or cardiovascular-event randomized controlled trial of GlyNAC in any human population.

Several outcome domains rest on a single trial, precluding internal replication.

Residual uncertainty

The main limitation is not only the size of the retained corpus, but also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some are indirect or model-system evidence. The paper therefore avoids treating all sources as equivalent. Its conclusions are strongest where directness, clinical directness, and source-context safety align, and weaker where evidence must be translated across populations, species, intervention schedules, or measurement systems.

The limitations identify evidence gaps, missing populations, indirect endpoints, and unresolved follow-up windows. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Conclusion

For glynac, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.

Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

In animal/preclinical evidence, additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Xu 2023, Kumar 2022, Studenski 2011, Tinetti 1988, Ioannidis 2005.

References

• Xu 2023. Glycine and N-Acetylcysteine (GlyNAC) Combined with Body Weight Support Treadmill Training Improved Spinal Cord and Skeletal Muscle Structure and Function in Rats with Spinal Cord Injury. Nutrients, 2023. DOI: 10.3390/nu15214578. PMID: 37960231.
• Xu 2024. The Effect of Glycine and N-Acetylcysteine on Oxidative Stress in the Spinal Cord and Skeletal Muscle After Spinal Cord Injury. Inflammation, 2024. DOI: 10.1007/s10753-023-01929-9. PMID: 37975960.
• Kumar 2020. Supplementing Glycine and N-acetylcysteine (GlyNAC) in Aging HIV Patients Improves Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Endothelial Dysfunction, Insulin Resistance, Genotoxicity, Strength, and Cognition: Results of an Open-Label Clinical Trial. Biomedicines, 2020. DOI: 10.3390/biomedicines8100390. PMID: 33007928.
• Kumar 2022. GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage. Nutrients, 2022. DOI: 10.3390/nu14051114. PMID: 35268089.
• Kumar 2021. Glycine and N‐acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine, 2021. DOI: 10.1002/ctm2.372. PMID: 33783984.
• Kumar 2023. GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging. Antioxidants, 2023. DOI: 10.3390/antiox12051042. PMID: 37237908.
• Sekhar 2022. GlyNAC (Glycine and N -Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants, 2022. DOI: 10.3390/antiox11010154. PMID: 35052658.
• Lizzo 2022. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Frontiers in Aging, 2022. DOI: 10.3389/fragi.2022.852569. PMID: 35821844.
• Wang 2026. Effect of heat stress and GlyNAC supplementation on jejunal morphology, hepatic inflammation infiltration and distribution of GSH content in chickens. Poultry Science, 2026. DOI: 10.1016/j.psj.2026.106910. PMID: 41980553.
• Kumar 2021b. Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N -Acetylcysteine) Supplementation. Antioxidants, 2021. DOI: 10.3390/antiox11010050. PMID: 35052554.
• Angelini 2024. Sex Differences in Response to Diet Enriched With Glutathione Precursors in the Aging Heart. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2024. DOI: 10.1093/gerona/glae258. PMID: 39492659.
• CORRECTING 2019. CORRECTING GLUTATHIONE DEFICIENCY AND MITOCHONDRIAL DYSFUNCTION IN OLDER HUMANS: A RANDOMIZED CLINICAL TRIAL. 2019.
• CORRECTING 2019b. CORRECTING GLUTATHIONE DEFICIENCY IN AGING: IMPACT ON MITOCHONDRIA, STRENGTH, INFLAMMATION AND METABOLIC DEFECTS. 2019.
• Sekhar 2022b. GLYNAC SUPPLEMENTATION IN OLDER ADULTS PROTECTS FROM MEAL DRIVEN OXIDATIVE STRESS AND INFLAMMATION: RESULTS OF A RCT. Innovation in Aging, 2022. DOI: 10.1093/geroni/igac059.2933.
• Sekhar 2021. Supplementing glycine and N-acetylcysteine (GlyNAC) rapidly improves health-related quality of life and lowers perception of fatigue in patients with HIV. AIDS, 2021. DOI: 10.1097/qad.0000000000002939. PMID: 34185721.
• Gut 2021. Effects of glycine and n-acetylcysteine on glutathione levels and mitochondrial energy metabolism in healthy aging. Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2574.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Tinetti 1988. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. DOI: 10.1056/NEJM198812293192604. PMID: 3205267.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.